Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research note released on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Stock Performance

Shares of EVGN stock opened at $1.90 on Friday. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $10.40. The firm has a market capitalization of $10.19 million, a PE ratio of -0.43 and a beta of 1.30. The stock’s 50-day simple moving average is $1.70 and its 200-day simple moving average is $3.26.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.